Histopathologic quantification of viable tumor versus treatment effect in surgically resected recurrent glioblastoma.
Stephen J BagleyRobert D SchwabErnest NelsonAngela N ViaeneZev A BinderRobert A LustigDonald M O'RourkeSteven BremArati S DesaiMacLean P NasrallahPublished in: Journal of neuro-oncology (2018)
In patients with glioblastoma undergoing repeat resection following chemoradiotherapy, high Ki-67 index in the recurrent specimen, short time to recurrence, and poor PS are independently associated with worse OS. Histopathologic quantification of viable tumor versus therapy-related changes has limited prognostic influence.